Developer docs
API playgroundTry for free, no card

Search company profiles

Galen Partners

Full company profile

uuid0002785

Namestring
Galen Partners
Legal namestring
Galen Partners
Websiteurl
galen.com
Company typeenum
Private
Founded yearint
1990
Descriptiontext

Galen Partners is a privately held, healthcare-exclusive growth equity investment firm founded in 1990 and headquartered in Stamford, Connecticut. The firm has raised six dedicated funds totaling nearly $1 billion in aggregate committed capital and has built a portfolio of more than 80 healthcare companies with an aggregate market value exceeding $10 billion. Galen is led by three Managing Directors (Philip Borden, David Jahns, Zubeen Shroff) supported by a CFO, two founding-era senior advisors, and a 15-member Special Investment Partner (SIP) bench of senior healthcare operators. The firm targets proven growth-stage healthcare companies with revenues above $10 million and EBITDA between $0 and $9 million, deploying capital through majority recapitalizations, growth equity, and buyouts across five verticals: Healthcare IT, Medical Technology, Outsourcing, Healthcare Services, and Specialty Products.

The firm's core product is its "Collaborative Capital" approach, a service methodology that pairs equity capital with hands-on operating support in eight areas: growth strategy, recruiting and team-building, new customer introductions, operational improvements, forecasting and budgeting, M&A support, outsourced business development, and exit-value maximization. The SIP network functions as a deal-sourcing and operating-partner channel that generalist peers cannot easily replicate. Galen has no proprietary technology platform of its own; its technology exposure is through portfolio companies that include AI-enabled diagnostics (CDx's WATS3D), perinatal AI (PeriGen), digital health (Sharecare), medical image exchange (lifeIMAGE), and enterprise telehealth (historically InTouch Health, exited to Teladoc in 2020 for ~$600M).

Galen's revenue model is a traditional fund management business: management fees on committed or invested capital across its six funds, supplemented by lumpy carried interest tied to portfolio realizations such as the Pyxis/Cardinal Health exit, Taro Pharmaceutical's public listing, and the Teladoc Health acquisition of InTouch Health. Distribution and deal flow come from direct founder-to-founder outreach, the SIP network, and healthcare-specialized legal and financial advisors. The firm is not pursuing seed or early-stage healthcare deals and is exclusively a US-domestic investor.

Short descriptiontext

Stamford, Connecticut-based Galen Partners is a healthcare growth equity firm founded in 1990. It has raised six funds totaling nearly $1 billion and invests in proven healthcare companies (revenues above $10M) across five verticals using a Collaborative Capital approach.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStamford, United States
HQ citystring
Stamford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare growth equity, venture capital investing, growth stage investments, healthcare private equity, portfolio company management
Industry1 code
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
NAICS code1 code
  • Other Insurance Funds525190
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Growth Equity / Venture Capital
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Healthcare growth equity fund management
TypeManaged Services
Description

Galen raises dedicated healthcare-focused growth equity funds (six funds to date, totaling nearly $1 billion in committed capital since 1990) and invests capital into healthcare companies. Returns are generated through a combination of ongoing fund management activities and realized gains from portfolio company exits, IPOs, M&A, and recapitalizations.

galen.com
2Operating support and value creation services
TypeProfessional Services
Description

Beyond capital, Galen provides Collaborative Capital services — growth strategy, recruiting, customer introductions, operational improvements, M&A advisory and exit planning — which underpin the firm's value capture in portfolio company outcomes.

galen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Bespoke negotiated investments in healthcare growth companies with revenues >$10M and EBITDA between $0 and $9M.
ModelOther
Notes

Investment size, equity stake, and structure tailored to each company's particular needs; financial terms of majority recapitalizations and acquisitions (CDx, SMP, Evolve) have not been disclosed.

galen.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Galen Partners is a healthcare-focused growth equity investment firm that raises dedicated funds from limited partners and invests growth-stage capital into US-headquartered healthcare companies with revenues greater than $10 million and EBITDA between $0 and $9 million. Beyond capital, the firm deploys a "Collaborative Capital" approach that bundles eight categories of hands-on operating support — growth strategies, recruiting and team building, new customer introductions, operational improvements, forecasting/budgeting, acquisitions, outsourced business development, and exit-value maximization — into a bespoke investment structure tailored to each founder's needs. Galen has raised six dedicated funds totaling nearly $1 billion since 1990 and built a portfolio of more than 80 healthcare companies across Healthcare IT, Medical Technology, Outsourcing, Healthcare Services, and Specialty Products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over $10 billion aggregate portfolio market value across 80+ companies
+4 more records
Product overview1 text field

Galen Partners is a healthcare-focused growth equity investment firm (not a technology product company), founded in 1990 and headquartered in Stamford, CT. The firm's offering is a single platform — its "Collaborative Capital" investment approach — deployed across six dedicated funds totaling nearly $1 billion, which has built a portfolio of 80+ healthcare companies organized into five investment verticals: the Healthcare IT (e.g., Sharecare, lifeIMAGE, InTouch Health), Medical Technology (e.g., CDx Diagnostics, Tactile Medical, MiniMed), Outsourcing (e.g., Stericycle, MedAssets), Healthcare Services (e.g., Evolve Treatment Centers), and Specialty Products (e.g., SMP Pharmacy Solutions, Quotient) portfolio categories. Beyond capital, Galen's Collaborative Capital service methodology bundles operational support across growth strategy, team building, customer introductions, operational improvements, forecasting/budgeting, acquisitions, business development, and exit maximization. The firm's portfolio companies span proprietary AI-powered diagnostic platforms (CDx's WATS3D), digital health engagement platforms (Sharecare), perinatal AI monitoring (PeriGen), and clinical imaging interoperability (lifeIMAGE).

Product and service7 records
1Collaborative Capital
CategoryInvestment Service Methodology
Description

Galen's flagship investment service methodology that combines growth equity capital with hands-on operating support across eight functional areas: growth strategies, recruiting and team building, new customer introductions, operational improvements, forecasting/budgeting, acquisitions, outsourced business development, and exit-value maximization. Provided to founders and management teams of healthcare growth-stage companies.

2Galen Healthcare Growth Equity Funds
CategoryInvestment Fund Platform
Description

Six dedicated healthcare-focused growth equity funds raised since 1990 totaling nearly $1 billion in committed capital. Investments target US healthcare companies with revenues greater than $10 million and EBITDA between $0 and $9 million, organized across five investment verticals: Healthcare IT, Medical Technology, Outsourcing, Healthcare Services, and Specialty Products. To date, 80+ portfolio companies have been backed with over $10 billion in aggregate portfolio market value.

3Healthcare IT Investment Vertical
CategoryHealthcare IT Investment Vertical
Description

One of five Galen healthcare investment verticals, covering growth equity investments in healthcare IT companies including telehealth (InTouch Health), digital health platforms (Sharecare, Dakim BrainFitness), medical image exchange and clinical data networks (Life Image / lifeIMAGE), and perinatal AI clinical decision support (PeriGen). Target investments are US healthcare growth companies with revenues >$10M and EBITDA $0–$9M.

4Medical Technology Investment Vertical
CategoryMedical Technology Investment Vertical
Description

One of five Galen healthcare investment verticals, covering growth equity investments in medical devices, diagnostics, and capital equipment, with portfolio companies including Cardiva Medical, SonaCare, DJO, ONI, Unisyn, CDx Diagnostics, Aperio, MiniMed, Pyxis, Tactile Medical (Tactile Systems), CryoLife, National Rehab Equipment, and Soteira.

5Outsourcing Investment Vertical
CategoryOutsourcing Investment Vertical
Description

One of five Galen healthcare investment verticals, covering growth equity investments in healthcare outsourcing and services firms such as Consensys, Daou, Eduneering, Stericycle, MedAssets, and Chamberlin Edmonds.

6Healthcare Services Investment Vertical
CategoryHealthcare Services Investment Vertical
Description

One of five Galen healthcare investment verticals, covering growth equity investments in healthcare services and providers, with portfolio companies including Evolve Treatment Centers (adolescent behavioral health, acquired 2020), ParadigmHealth, IDC, Vitas, IMG, Lumenos, Qmed, Theratech, PET DRX Corp, and CBLPath.

7Specialty Products Investment Vertical
CategorySpecialty Products Investment Vertical
Description

One of five Galen healthcare investment verticals, covering growth equity investments in specialty pharmaceuticals, fertility pharmacy, generic drugs, and consumer health products, with portfolio companies including SMP Pharmacy Solutions, Quotient (Quotient BioDiagnostics), JDS Pharmaceuticals, Nautilus Neurosciences, Acura Pharmaceuticals, SHPI, Vasogen, Vivus, Cambrooke, Ocular Sciences, Dow Pharmaceutical Sciences, and Taro Pharmaceuticals.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Private equity firm with a significant healthcare and specialty industrials franchise. Comparable to Galen in healthcare services and specialty products investing, though broader in sector mandate.

TypeDirect peer
Description

One of the largest and longest-tenured healthcare-dedicated private equity/growth equity firms in the US. Directly comparable to Galen as a healthcare-only growth investor operating multiple funds and deploying capital across healthcare services, IT, and medical technology.

TypeDirect peer
Description

US growth equity firm with a sizable healthcare franchise (defense, health services, pharma services). Mirrors Galen's growth-stage mandate, collaborative operating model, and healthcare vertical orientation.

TypeDirect peer
Description

US private equity firm exclusively focused on healthcare (healthcare services, MedTech, pharma services). Closely comparable to Galen's healthcare-only mandate and growth-stage investment focus.

TypeDirect peer
Description

Healthcare-dedicated growth equity firm based in Nashville. Directly comparable to Galen in targeting mid-to-late growth-stage healthcare companies and providing operating partnership beyond capital.

TypeDirect peer
Description

Healthcare-focused middle-market private equity firm. Similar to Galen in healthcare-only mandate and concentration in growth equity / recapitalization transactions across healthcare services and pharma.

TypeDirect peer
Description

Healthcare-focused growth equity firm investing in health IT, services, and medical technology. Comparable to Galen in vertical specialization and growth-stage orientation, with a particular emphasis on healthcare IT.

TypeDirect peer
Description

Private equity firm focused on financial services and healthcare. Comparable to Galen in growth-stage healthcare investing and providing operating support alongside capital.

TypeBroad incumbent
Description

Large global growth equity investor with a meaningful healthcare practice. Comparable to Galen in growth-stage healthcare investing (e.g., backing Sharecare-adjacent businesses), though broader in scope and significantly larger in AUM.

TypeDirect peer
Description

Healthcare-dedicated venture and growth capital fund affiliated with Ascension Health. Comparable to Galen in healthcare-only mandate and growth-stage equity investing, though typically backed by a strategic health system LP base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment8 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment28 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Galen Partners

Healthcare Growth Equity / Venture Capitalgalen.com

Stamford, Connecticut-based Galen Partners is a healthcare growth equity firm founded in 1990. It has raised six funds totaling nearly $1 billion and invests in proven healthcare companies (revenues above $10M) across five verticals using a Collaborative Capital approach.

What Galen Partners does

Galen Partners is a privately held, healthcare-exclusive growth equity investment firm founded in 1990 and headquartered in Stamford, Connecticut. The firm has raised six dedicated funds totaling nearly $1 billion in aggregate committed capital and has built a portfolio of more than 80 healthcare companies with an aggregate market value exceeding $10 billion. Galen is led by three Managing Directors (Philip Borden, David Jahns, Zubeen Shroff) supported by a CFO, two founding-era senior advisors, and a 15-member Special Investment Partner (SIP) bench of senior healthcare operators. The firm targets proven growth-stage healthcare companies with revenues above $10 million and EBITDA between $0 and $9 million, deploying capital through majority recapitalizations, growth equity, and buyouts across five verticals: Healthcare IT, Medical Technology, Outsourcing, Healthcare Services, and Specialty Products.

The firm's core product is its "Collaborative Capital" approach, a service methodology that pairs equity capital with hands-on operating support in eight areas: growth strategy, recruiting and team-building, new customer introductions, operational improvements, forecasting and budgeting, M&A support, outsourced business development, and exit-value maximization. The SIP network functions as a deal-sourcing and operating-partner channel that generalist peers cannot easily replicate. Galen has no proprietary technology platform of its own; its technology exposure is through portfolio companies that include AI-enabled diagnostics (CDx's WATS3D), perinatal AI (PeriGen), digital health (Sharecare), medical image exchange (lifeIMAGE), and enterprise telehealth (historically InTouch Health, exited to Teladoc in 2020 for ~$600M).

Galen's revenue model is a traditional fund management business: management fees on committed or invested capital across its six funds, supplemented by lumpy carried interest tied to portfolio realizations such as the Pyxis/Cardinal Health exit, Taro Pharmaceutical's public listing, and the Teladoc Health acquisition of InTouch Health. Distribution and deal flow come from direct founder-to-founder outreach, the SIP network, and healthcare-specialized legal and financial advisors. The firm is not pursuing seed or early-stage healthcare deals and is exclusively a US-domestic investor.

Galen Partners firmographics

Firmographics
Name
Galen Partners
Legal name
Galen Partners
Website
https://galen.com
Company type
Private
Founded year
1990
Operating status
Operating
Headcount range
11–50 employees
Short description
Stamford, Connecticut-based Galen Partners is a healthcare growth equity firm founded in 1990. It has raised six funds totaling nearly $1 billion and invests in proven healthcare companies (revenues above $10M) across five verticals using a Collaborative Capital approach.
Ownership category
akta.pro rank

Galen Partners industry classification

Industry
Product category
Healthcare Growth Equity / Venture Capital
NAICS
Other Insurance Funds (525190)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity

Keywords

  • Healthcare growth equity
  • Venture capital investing
  • Growth stage investments
  • Healthcare private equity
  • Portfolio company management

Where Galen Partners is headquartered

Location

Headquarters

HQ city
Stamford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Galen Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Healthcare growth equity fund management: Galen raises dedicated healthcare-focused growth equity funds (six funds to date, totaling nearly $1 billion in committed capital since 1990) and invests capital into healthcare companies. Returns are generated through a combination of ongoing fund management activities and realized gains from portfolio company exits, IPOs, M&A, and recapitalizations.
  2. Operating support and value creation services: Beyond capital, Galen provides Collaborative Capital services — growth strategy, recruiting, customer introductions, operational improvements, M&A advisory and exit planning — which underpin the firm's value capture in portfolio company outcomes.

Pricing tiers

ModelBillingPrice
Other—Bespoke negotiated investments in healthcare growth companies with revenues >$10M and EBITDA between $0 and $9M.

Go-to-market motion4 records

Distribution channels3 records

Marketing channels5 records

Galen Partners product offering

Product offering

Core offering

Galen Partners is a healthcare-focused growth equity investment firm that raises dedicated funds from limited partners and invests growth-stage capital into US-headquartered healthcare companies with revenues greater than $10 million and EBITDA between $0 and $9 million. Beyond capital, the firm deploys a "Collaborative Capital" approach that bundles eight categories of hands-on operating support — growth strategies, recruiting and team building, new customer introductions, operational improvements, forecasting/budgeting, acquisitions, outsourced business development, and exit-value maximization — into a bespoke investment structure tailored to each founder's needs. Galen has raised six dedicated funds totaling nearly $1 billion since 1990 and built a portfolio of more than 80 healthcare companies across Healthcare IT, Medical Technology, Outsourcing, Healthcare Services, and Specialty Products.

Product overview

Galen Partners is a healthcare-focused growth equity investment firm (not a technology product company), founded in 1990 and headquartered in Stamford, CT. The firm's offering is a single platform — its "Collaborative Capital" investment approach — deployed across six dedicated funds totaling nearly $1 billion, which has built a portfolio of 80+ healthcare companies organized into five investment verticals: the Healthcare IT (e.g., Sharecare, lifeIMAGE, InTouch Health), Medical Technology (e.g., CDx Diagnostics, Tactile Medical, MiniMed), Outsourcing (e.g., Stericycle, MedAssets), Healthcare Services (e.g., Evolve Treatment Centers), and Specialty Products (e.g., SMP Pharmacy Solutions, Quotient) portfolio categories. Beyond capital, Galen's Collaborative Capital service methodology bundles operational support across growth strategy, team building, customer introductions, operational improvements, forecasting/budgeting, acquisitions, business development, and exit maximization. The firm's portfolio companies span proprietary AI-powered diagnostic platforms (CDx's WATS3D), digital health engagement platforms (Sharecare), perinatal AI monitoring (PeriGen), and clinical imaging interoperability (lifeIMAGE).

Differentiator

Problem solved

Functional benefit

Products and services

  • Collaborative Capital Galen's flagship investment service methodology that combines growth equity capital with hands-on operating support across eight functional areas: growth strategies, recruiting and team building, new customer introductions, operational improvements, forecasting/budgeting, acquisitions, outsourced business development, and exit-value maximization. Provided to founders and management teams of healthcare growth-stage companies.
  • Galen Healthcare Growth Equity Funds Six dedicated healthcare-focused growth equity funds raised since 1990 totaling nearly $1 billion in committed capital. Investments target US healthcare companies with revenues greater than $10 million and EBITDA between $0 and $9 million, organized across five investment verticals: Healthcare IT, Medical Technology, Outsourcing, Healthcare Services, and Specialty Products. To date, 80+ portfolio companies have been backed with over $10 billion in aggregate portfolio market value.
  • Healthcare IT Investment Vertical One of five Galen healthcare investment verticals, covering growth equity investments in healthcare IT companies including telehealth (InTouch Health), digital health platforms (Sharecare, Dakim BrainFitness), medical image exchange and clinical data networks (Life Image / lifeIMAGE), and perinatal AI clinical decision support (PeriGen). Target investments are US healthcare growth companies with revenues >$10M and EBITDA $0–$9M.
  • Medical Technology Investment Vertical One of five Galen healthcare investment verticals, covering growth equity investments in medical devices, diagnostics, and capital equipment, with portfolio companies including Cardiva Medical, SonaCare, DJO, ONI, Unisyn, CDx Diagnostics, Aperio, MiniMed, Pyxis, Tactile Medical (Tactile Systems), CryoLife, National Rehab Equipment, and Soteira.
  • Outsourcing Investment Vertical One of five Galen healthcare investment verticals, covering growth equity investments in healthcare outsourcing and services firms such as Consensys, Daou, Eduneering, Stericycle, MedAssets, and Chamberlin Edmonds.
  • Healthcare Services Investment Vertical One of five Galen healthcare investment verticals, covering growth equity investments in healthcare services and providers, with portfolio companies including Evolve Treatment Centers (adolescent behavioral health, acquired 2020), ParadigmHealth, IDC, Vitas, IMG, Lumenos, Qmed, Theratech, PET DRX Corp, and CBLPath.
  • Specialty Products Investment Vertical One of five Galen healthcare investment verticals, covering growth equity investments in specialty pharmaceuticals, fertility pharmacy, generic drugs, and consumer health products, with portfolio companies including SMP Pharmacy Solutions, Quotient (Quotient BioDiagnostics), JDS Pharmaceuticals, Nautilus Neurosciences, Acura Pharmaceuticals, SHPI, Vasogen, Vivus, Cambrooke, Ocular Sciences, Dow Pharmaceutical Sciences, and Taro Pharmaceuticals.

Quantifiable outcome

  • Over $10 billion aggregate portfolio market value across 80+ companies
  • +4 more outcomes

Companies that use Galen Partners

Customer profile

Named customers10 records

Segments8 records

Ideal customer profiles1 record

Galen Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature2 records

Galen Partners partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Galen Partners competitors and assessment

Company assessment

Broad incumbents

  • Arsenal Capital Partners: Private equity firm with a significant healthcare and specialty industrials franchise. Comparable to Galen in healthcare services and specialty products investing, though broader in sector mandate.
  • General Atlantic: Large global growth equity investor with a meaningful healthcare practice. Comparable to Galen in growth-stage healthcare investing (e.g., backing Sharecare-adjacent businesses), though broader in scope and significantly larger in AUM.

Direct peers

  • Welsh, Carson, Anderson & Stowe: One of the largest and longest-tenured healthcare-dedicated private equity/growth equity firms in the US. Directly comparable to Galen as a healthcare-only growth investor operating multiple funds and deploying capital across healthcare services, IT, and medical technology.
  • New Mountain Capital: US growth equity firm with a sizable healthcare franchise (defense, health services, pharma services). Mirrors Galen's growth-stage mandate, collaborative operating model, and healthcare vertical orientation.
  • Linden Capital Partners: US private equity firm exclusively focused on healthcare (healthcare services, MedTech, pharma services). Closely comparable to Galen's healthcare-only mandate and growth-stage investment focus.
  • Cressey & Company: Healthcare-dedicated growth equity firm based in Nashville. Directly comparable to Galen in targeting mid-to-late growth-stage healthcare companies and providing operating partnership beyond capital.
  • Avista Capital Partners: Healthcare-focused middle-market private equity firm. Similar to Galen in healthcare-only mandate and concentration in growth equity / recapitalization transactions across healthcare services and pharma.
  • Health Velocity Capital: Healthcare-focused growth equity firm investing in health IT, services, and medical technology. Comparable to Galen in vertical specialization and growth-stage orientation, with a particular emphasis on healthcare IT.
  • Aquiline Capital Partners: Private equity firm focused on financial services and healthcare. Comparable to Galen in growth-stage healthcare investing and providing operating support alongside capital.
  • Ascension Ventures: Healthcare-dedicated venture and growth capital fund affiliated with Ascension Health. Comparable to Galen in healthcare-only mandate and growth-stage equity investing, though typically backed by a strategic health system LP base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Galen Partners social profiles

Digital presence

Galen Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Galen Partners leadership team

Management profile

Number of profiles

Profiles7 records

Galen Partners subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Galen Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Galen Partners M&A and investment

M&A and investment

M&A2 records

Investments28 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galen Partners

What does Galen Partners do?

Galen Partners is a healthcare-focused growth equity investment firm that raises dedicated funds from limited partners and invests growth-stage capital into US-headquartered healthcare companies with revenues greater than $10 million and EBITDA between $0 and $9 million. Beyond capital, the firm deploys a "Collaborative Capital" approach that bundles eight categories of hands-on operating support — growth strategies, recruiting and team building, new customer introductions, operational improvements, forecasting/budgeting, acquisitions, outsourced business development, and exit-value maximization — into a bespoke investment structure tailored to each founder's needs. Galen has raised six dedicated funds totaling nearly $1 billion since 1990 and built a portfolio of more than 80 healthcare companies across Healthcare IT, Medical Technology, Outsourcing, Healthcare Services, and Specialty Products.

Is Galen Partners a public or private company?

Galen Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Galen Partners founded?

Galen Partners was founded in 1990. It employs 11 to 50 people.

Where is Galen Partners based?

Galen Partners is headquartered in Stamford, United States, in the North America region.

How does Galen Partners make money?

Two revenue lines are on record. Healthcare growth equity fund management is the primary driver. The others are operating support and value creation services.

Who are Galen Partners's main competitors?

Broad incumbents on record are Arsenal Capital Partners and General Atlantic. Direct peers are Welsh, Carson, Anderson & Stowe, New Mountain Capital, Linden Capital Partners, Cressey & Company, Avista Capital Partners, Health Velocity Capital, Aquiline Capital Partners and Ascension Ventures.

Does Galen Partners have an API?

No public API is recorded for Galen Partners.

What industry is Galen Partners in?

Galen Partners's product category is Healthcare Growth Equity / Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 525190 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireGalen Partners completes acquisition of Evolve Treatment Centers, a leading provider of adolescent behavioral health services in CaliforniaGalen Partners acquired Evolve Treatment Centers, a California-based adolescent behavioral health provider. The deal aims to expand Evolve's CARF and Joint Commission-accredited services, citing a 400% national increase in adolescent suicide attempts since 2011.GlobeNewswireGalen Partners completes add-on acquisition for SMP Pharmacy Solutions, a niche-focused, high-touch specialty pharmacySMP Pharmacy Solutions completed an acquisition of Northridge Plaza Pharmacy, a fertility clinic pharmacy in California. The deal expands SMP's West Coast presence to meet high demand in the fertility market. Financial terms were not disclosed.GlobeNewswireGalen Partners completes investment in SMP Pharmacy Solutions, a niche-focused, high-touch specialty pharmacyGalen Partners completed a majority recapitalization of SMP Pharmacy Solutions, a specialty pharmacy focusing on niche areas like fertility. The financial terms were not disclosed, and SMP's CEO Armando Bardisa and COO Brian Brito will continue leading. The deal is the second investment out of Galen Fund VI.GlobeNewswireGalen Partners Completes Sale of Cambrooke TherapeuticsGalen Partners sold Cambrooke Therapeutics to Ajinomoto Co. on Nov. 10, 2017. The sale gives Cambrooke access to Ajinomoto's global nutrition and ingredient sciences expertise. Galen's investment was a platform opportunity along the food-drug continuum.GlobeNewswireGalen Partners Completes Majority Recapitalization of CDx DiagnosticsGalen Partners completed a majority recapitalization of CDx Diagnostics, a cancer diagnostics lab using neural-network-based microscopy. The deal's financial terms were not disclosed, and Galen named Tom Bologna as chairman and Jim Hutchinson as president. CDx's WATS3D test is four times more effective than standard biopsy at detecting esophageal precancer.VC News DailyTactile Systems Touches $10.4M Series BTactile Systems Technology Inc., a Minneapolis-based medical device company specializing in at-home lymphedema treatment, has secured $10.4 million in Series B financing led by Radius Ventures with participation from Galen Partners. The funding will support the acquisition of new lymphedema technology and intellectual property rights, enabling the company to update its product offerings and expand into treatments for other vascular diseases. The acquired technology has already received FDA 510(k) market clearance and a Medicare reimbursement code.VC News DailyQuotient Biodiagnostics Adds $11.2MQuotient Biodiagnostics Holdings Limited, a global transfusion diagnostics group based in Newtown, PA, has completed an $11.2 million growth equity financing round led by Galen Partners, a US-based healthcare venture capital firm. The funds will be used to expand US commercial operations, grow manufacturing and product development in Edinburgh, Scotland, and accelerate development of a next-generation automated transfusion diagnostics platform. As part of the deal, David Azad and John Wilkerson from Galen Partners, along with Thomas A. Bologna, will join Quotient's Board as Non-Executive Directors.FinSMEsLifeImage Completes $12M Second Funding RoundLifeImage, a Newton, MA-based SaaS medical image sharing platform, completed an $11.8M second funding round led by Cardinal Partners and Galen Partners. The company, which had raised $2.5M in April 2009 and $2M in January 2010, will use the funds to expand operations and strategic partnerships. Thomas McKinley and David Jahns joined the board.